Research Topics
| Jean Yves DouillardSummaryAffiliation: Institut Paoli-Calmettes Country: France Publications
| Collaborators
|
Detail Information
Publications
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialJean Yves Douillard
Centre Rene Gauducheau, Nantes, France
Lancet Oncol 7:719-27. 2006..We aimed to compare the effect of adjuvant vinorelbine plus cisplatin versus observation on survival in patients with completely resected NSCLC...
Update on European adjuvant trials with irinotecan for colorectal cancerJean Yves Douillard
Centre Rene Gauducheau, CRLCC Nantes Atlantique, St Herblain Nantes, France
Oncology (Williston Park) 16:13-5. 2002..This article will review the inclusion criteria and goal of these European trials. An update on accrual and on tolerance will also be provided...
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinibCharles S Harmon
Pfizer Oncology, La Jolla, CA, USA
J Transl Med 9:120. 2011..In a phase II study of sunitinib in advanced HCC, we evaluated the plasma pharmacodynamics of five proteins related to the mechanism of action of sunitinib and explored potential correlations with clinical outcome...
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II studyJ Y Douillard
Centre Rene Gauducheau, Saint Herblain, France
Ann Oncol 16:81-9. 2005..This phase II trial compared docetaxel-cisplatin (DC) with vinorelbine-cisplatin (VC), both as first-line therapy followed by cross-over at progression to single-agent vinorelbine or docetaxel in advanced non-small-cell lung cancer (NSCLC)...
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trialsJean Yves Douillard
Centre R Gauducheau, St Herblain, France
J Thorac Oncol 2:939-46. 2007..To compare the impact on overall survival (OS) of docetaxel-based chemotherapy versus vinca alkaloid-based regimens for first-line therapy of advanced non-small cell lung cancer...
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?Jean Yves Douillard
Department of Medical Oncology, Centre R Gauducheau, St Herblain, France
Clin Colorectal Cancer 7:206-11. 2008..Patient preference, quality of life, and cost of treatment could also be considered in this setting, wherein most of the patients are not in a curative situation...
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin EvaluationJean Yves Douillard
Department of Medical Oncology, Centre R Gauducheau, St Herblain, France
J Thorac Oncol 5:220-8. 2010..Patients randomized to cisplatin-vinorelbine or observation were the largest subgroup (41%) and the most homogeneous in terms of drug doses and eligibility...
ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignanciesJ Y Douillard
CRLCC Nantes Atlantique, Nantes Saint Herblain, France
Eur J Cancer 38:S25-31. 2002..6%), neutropenia (36.4%) and anaemia (18.2%). No objective responses were observed in either trial, but disease stabilisation occurred in 29.2% and 27.3% of patients in the vinorelbine and topotecan trials, respectively...
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean Yves Douillard
Centre Rene Gauducheau, Nantes, France
J Clin Oncol 28:4697-705. 2010....
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJean Yves Douillard
Centre Rene Gauducheau, Nantes, France
J Clin Oncol 20:3605-16. 2002..Safety was also compared...
Irinotecan-based regimens in the adjuvant therapy of colorectal cancerJean Yves Douillard
Department of Medical Oncology, Centre R Gauducheau, Nantes St Herblain, France
Clin Colorectal Cancer 5:S34-7. 2005..These results should provide important new insights as to how to manage stage II/III colon cancer...
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR studyJaafar Bennouna
Centre Rene Gauducheau, Nantes, France
Clin Colorectal Cancer 11:38-44. 2012..This prospective phase II study assessed the efficacy and safety of bevacizumab plus chemotherapy regimens commonly used in the second-line treatment of metastatic colorectal cancer (mCRC)...
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Jean Yves Douillard
Centre R Gauducheau, Nantes, France
Int J Radiat Oncol Biol Phys 72:695-701. 2008..To study the impact of postoperative radiation therapy (PORT) on survival in the Adjuvant Navelbine International Trialist Association (ANITA) randomized study of adjuvant chemotherapy...
Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trialJaafar Bennouna
Centre Rene Gauducheau, Bd J Monod, 44805 Nantes, France
Lung Cancer 74:30-4. 2011..Data issued from the survival outcome in the ANITA trial are reported according to histology in observation (n=433) and adjuvant chemotherapy arms (n=407)...
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimensJaafar Bennouna
Medical Oncology Branch, Centre Rene Gauducheau, Bd J Monod, 44805 Saint Herblain, France
Invest New Drugs 29:1021-8. 2011..To assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with metastatic colorectal cancer who had failed one or two previous chemotherapeutic regimens that included oxaliplatin and/or irinotecan...
Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapyJaafar Bennouna
Centre Rene Gauducheau, Nantes Saint Herblain, France
Expert Rev Anticancer Ther 3:505-17. 2003..This review will focus upon new anticancer drugs, some of them with original mechanism of action, and steps towards the goal of better understanding and anticipating new treatments in colorectal carcinoma...
Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivoAhmed Hamai
Institut National de la Sante et de la Recherche Medicale, Unité 1102, institut de cancérologie de l Ouest, Saint Herblain, France
Cancer Res 72:1059-63. 2012....
Repeat hepatectomy for colorectal liver metastasesAntoine Hamy
Clinique Chirurgicale 1, Centre Hospitalier Universitaire Nord, Nantes, France
Int Surg 90:189-97. 2005..Survival rates for repeat resections of colorectal liver metastases in selected patients were comparable with those obtained after resection of a first liver metastasis...
The role of UFT in metastatic colorectal cancerJaafar Bennouna
Centre R Gauducheau, St Herblain, France
Oncology 76:301-10. 2009..UFT can be considered a rational replacement for intravenous 5-FU in the first- and second-line treatment of patients with mCRC...
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)Stephane Culine
Department of Medical Oncology, Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5, France
J Clin Oncol 21:3479-82. 2003..To evaluate the efficacy and toxicity of novel chemotherapy combinations including cisplatin with gemcitabine (GC) or irinotecan (IC) for patients with carcinomas of an unknown primary site...
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'ImmunotherapieSylvie Negrier
Cytokines and Cancer Research Unit, INSERM U 590 and Medical Oncology Department, Cedex 08, France
J Clin Oncol 22:2371-8. 2004..Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6)...
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieSylvie Negrier
Department of Biostatistics, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08 France
World J Urol 23:161-5. 2005..Patients who combine at least three of these factors have over 80% probability of rapid progression despite treatment. We think that these results must be taken into account for cytokine treatment decision...
[Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]Sylvie Negrier
Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69373 Lyon
Prog Urol 12:213-8. 2002..c. cytokine regimens are therefore fairly disappointing. These results were taken into account in the ongoing evaluation programme (Percy programme) based on patient selection as a function of prognostic factors...
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancerJean-Yves Douillard
Centre Rene Gauducheau, Nantes, France
Lung Cancer 46:361-8. 2004..As planned, patient accrual continued to further investigate the effect of BMS-275291 on overall and progression-free survival in a phase III setting...
Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancerJaafar Bennouna
, Boulevard J. Monod 44 805, Nantes-Saint-Herblain, France
Int J Clin Oncol 7:236-44. 2002
Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe FrançaisAlain Ravaud
Department of Medicine, Institut Bergoni, Bordeaux, France
Cancer 95:2324-30. 2002..Although SC IL-2 regimens are used widely, their interest remains to be determined...
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyCornelis J A Punt
Department of Medical Oncology, University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen, Netherlands
Lancet 360:671-7. 2002..We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients...
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18Natasha B Leighl
National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
J Clin Oncol 23:2831-9. 2005..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]Masahiro Fukuoka
Fourth Department of Internal Medicine, Kinki University School of Medicine, 377 2 Ohnohigashi Osakasayama, Osaka 589, Japan
J Clin Oncol 21:2237-46. 2003....
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative GroupJean Pierre Pignon
Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
J Clin Oncol 26:3552-9. 2008..The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy...
Potential regional differences for the tolerability profiles of fluoropyrimidinesDaniel G Haller
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 26:2118-23. 2008....
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trialsGunnar Folprecht
University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
J Clin Oncol 26:1443-51. 2008..Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)...
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration scheduleMarie Christine Etienne Grimaldi
Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France
Clin Pharmacokinet 46:953-63. 2007....
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trialsCornelis J A Punt
Department of Medical Oncology, Radboud University Nijmegen Medical Center, PO Box 9101 6500 HB Nijmegen, The Netherlands
J Natl Cancer Inst 99:998-1003. 2007..The proposed guidelines may add to the quality and cross-comparability of future studies of adjuvant treatments for cancer...
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa
Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
J Clin Oncol 24:4293-300. 2006..This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients...
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancerLuis Paz-Ares
Servicio de Oncologia Medica, Doce de Octubre University Hospital, Madrid, Spain
J Clin Oncol 24:1428-34. 2006....
[Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients]Alain Depierre
Bull Cancer 90:151-66. 2003..This is a short version of the SOR guideline covering diagnosis, treatment and follow-up and includes the algorithms for the management of patients with non-small cell lung cancer...
[2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer]Jeanne Marie Brechot
FNCLCC, Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13, France
Bull Cancer 89:857-67. 2002..The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery...
